PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial

NCT02624973

Last updated date
Study Location
Akershus University Hospital
Lørenskog, Akershus, , Norway
Contact
1-800-718-1021

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Breast Cancer
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Previously untreated, histologically confirmed non-inflammatory breast cancer, >4 cm in diameter and /or metastatic ipsilateral axillary deposits for which the smallest diameter of the largest node >2 cm by CT or ultrasound scan.

- WHO performance status 0-1

- Known tumor ER, PGR, HER2 and TP53 status.

- Known tumor Ki67 percentage (if ER/PGR>50% and TP53 wt status).

- Distant metastasis not suspected. Patients will undergo radiology exams during screening phase, after signing the informed consent.

- Age >18 years

- Patients must have clinically and/or radiographically documented measurable breast cancer according to RECIST.

- Radiology studies (CT thorax/abdomen and bone scintigraphy/bone scan) must be performed within 28 days prior to registration.

- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial

- Before patient registration/randomization, written informed consent must be given according to national and local regulations.

- For arms B-H:

- Neutrophils > 1.5 x 109/L

- Platelets > 100 x 109/L

- Bilirubin < 2 x upper limit normal (ULN). For patients with Gilbert´s syndrome bilirubin >2 x ULN is accepted if there is no evidence of biliary obstruction.

- Serum creatinine < 1.5 x ULN

- ALT and Alk Phos (ALP) <2.5 x ULN

- INR < 1.5

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Unstable angina pectoris or heart failure


- Other co-morbidity that, based on the assessment of the treating physician, may
preclude the use of chemotherapy at actual doses.


- Pregnant or lactating patients can not be included.


- Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or
embolism does not exclude patients from inclusion, unless patient is considered unfit
by study oncologist.


- Patient not able to give an informed consent or comply with study regulations as
deemed by study investigator.


- Active cystitis (to be treated upfront)


- Active bacterial infections


- Urinary obstruction

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Based on your search, you may also be interested in

Breast CancerNeoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB Breast Cancer, HR+, HER2 -
NCT03819010
  1. Badalona, Barcelona
  2. Madrid,
  3. Valencia,
  4. Oporto,
Female
18 Years+
years
MULTIPLE SITES
Breast CancerPALbociclib CoLlaborative Adjuvant Study
NCT02513394
  1. Mobile, Alabama
  2. Mobile, Alabama
  3. Anchorage, Alaska
  4. Anchorage, Alaska
  5. Phoenix, Arizona
  6. Greenbrae, California
  7. Greenbrae, California
  8. La Jolla, California
  9. Los Angeles, California
  10. Oakland, California
  11. Palo Alto, California
  12. Roseville, California
  13. Sacramento, California
  14. San Diego, California
  15. San Diego, California
  16. San Diego, California
  17. San Francisco, California
  18. San Francisco, California
  19. San Leandro, California
  20. Santa Clara, California
  21. South San Francisco, California
  22. Stanford, California
  23. Vallejo, California
  24. Walnut Creek, California
  25. Denver, Colorado
  26. Hartford, Connecticut
  27. New Britain, Connecticut
  28. Newark, Delaware
  29. Washington, District of Columbia
  30. Washington, District of Columbia
  31. Clearwater, Florida
  32. Jacksonville, Florida
  33. Miami Beach, Florida
  34. Miami, Florida
  35. Orlando, Florida
  36. Atlanta, Georgia
  37. Chicago, Illinois
  38. Chicago, Illinois
  39. Chicago, Illinois
  40. Decatur, Illinois
  41. Harvey, Illinois
  42. Joliet, Illinois
  43. Park Ridge, Illinois
  44. Peoria, Illinois
  45. Rockford, Illinois
  46. Skokie, Illinois
  47. Skokie, Illinois
  48. Urbana, Illinois
  49. Indianapolis, Indiana
  50. Muncie, Indiana
  51. Ames, Iowa
  52. Ames, Iowa
  53. Cedar Rapids, Iowa
  54. Des Moines, Iowa
  55. Waterloo, Iowa
  56. Lexington, Kentucky
  57. Louisville, Kentucky
  58. New Orleans, Louisiana
  59. Bangor, Maine
  60. Scarborough, Maine
  61. Annapolis, Maryland
  62. Baltimore, Maryland
  63. Baltimore, Maryland
  64. Baltimore, Maryland
  65. Baltimore, Maryland
  66. Baltimore, Maryland
  67. Baltimore, Maryland
  68. Bethesda, Maryland
  69. Salisbury, Maryland
  70. Silver Spring, Maryland
  71. Boston, Massachusetts
  72. Boston, Massachusetts
  73. Boston, Massachusetts
  74. Boston, Massachusetts
  75. Lowell, Massachusetts
  76. Plymouth, Massachusetts
  77. Ann Arbor, Michigan
  78. Grand Rapids, Michigan
  79. Livonia, Michigan
  80. Duluth, Minnesota
  81. Rochester, Minnesota
  82. Rochester, Minnesota
  83. Saint Cloud, Minnesota
  84. Saint Louis Park, Minnesota
  85. Saint Louis Park, Minnesota
  86. Kansas City, Missouri
  87. Rolla, Missouri
  88. Saint Louis, Missouri
  89. Saint Louis, Missouri
  90. Saint Louis, Missouri
  91. Springfield, Missouri
  92. Omaha, Nebraska
  93. Concord, New Hampshire
  94. Hooksett, New Hampshire
  95. Lebanon, New Hampshire
  96. Lebanon, New Hampshire
  97. Englewood, New Jersey
  98. Hackensack, New Jersey
  99. Albuquerque, New Mexico
  100. Albuquerque, New Mexico
  101. Bronx, New York
  102. Buffalo, New York
  103. East Syracuse, New York
  104. Jamaica, New York
  105. New Hyde Park, New York
  106. New York, New York
  107. New York, New York
  108. New York, New York
  109. Oneonta, New York
  110. Syracuse, New York
  111. Charlotte, North Carolina
  112. Durham, North Carolina
  113. Greensboro, North Carolina
  114. Pinehurst, North Carolina
  115. Rapid City, North Dakota
  116. Cleveland, Ohio
  117. Cleveland, Ohio
  118. Columbus, Ohio
  119. Mayfield Heights, Ohio
  120. Lawton, Oklahoma
  121. Oklahoma City, Oklahoma
  122. Oklahoma City, Oklahoma
  123. Portland, Oregon
  124. Dunmore, Pennsylvania
  125. Hershey, Pennsylvania
  126. Lancaster, Pennsylvania
  127. Philadelphia, Pennsylvania
  128. Philadelphia, Pennsylvania
  129. Philadelphia, Pennsylvania
  130. Philadelphia, Pennsylvania
  131. Pittsburgh, Pennsylvania
  132. Pittsburgh, Pennsylvania
  133. Wyomissing, Pennsylvania
  134. York, Pennsylvania
  135. Providence, Rhode Island
  136. Providence, Rhode Island
  137. Columbia, South Carolina
  138. Aberdeen, South Dakota
  139. Rapid City, South Dakota
  140. Sioux Falls, South Dakota
  141. Nashville, Tennessee
  142. Nashville, Tennessee
  143. Houston, Texas
  144. Houston, Texas
  145. Houston, Texas
  146. Laredo, Texas
  147. Salt Lake City, Utah
  148. Fairfax, Virginia
  149. Richmond, Virginia
  150. Charleston, West Virginia
  151. Appleton, Wisconsin
  152. Green Bay, Wisconsin
  153. La Crosse, Wisconsin
  154. Madison, Wisconsin
  155. Milwaukee, Wisconsin
  156. Milwaukee, Wisconsin
  157. Racine, Wisconsin
  158. Waukesha, Wisconsin
  159. Waukesha, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Official Title  ICMJE PErsonalized TREatment of High-risk MAmmary Cancer - the PETREMAC Trial
Brief Summary Breast cancer is an optimal "model disease" for studying personalized medicine. Breast cancer was the first malignancy for which a predictive factor forecasting response to therapy was identified nearly 50 years ago; the expression of the estrogen receptor (ER). Furthermore, breast cancer is by far the malignancy in which prognostic and predictive factors have been most extensively studied. Primary medical treatment (pre-surgical medical therapy) offers a unique setting to explore predictive factors due to the fact that primary breast cancers are easily accessible to repeated tissue sampling and evaluation of therapy response both clinically and radiologically. For many years, the investigators have studied predictive factors in primary medical treatment of breast cancer. In the present project, the investigators will implement a new trial concept where the current knowledge from previous trials with respect to predictive markers (hormone receptors, HER2; TP53, CHEK2 and RB1), will be combined with massive parallel sequencing (MPS). Thereby, the investigators aim to design the "next-generation" primary medical treatment where 1) therapy regimens are individualized based on a limited number of known predictive factors and, 2) MPS is used to explore additional predictive factors and their co-regulators in order to fully identify the mechanisms of drug sensitivity / resistance across individual tumours and pave the way for further personalized breast cancer therapy in the future. As for the new era of "genomic medicine", the current trial concept will allow individual tumours to be characterized by their unique gene mutation / epigenetic modification profile upfront, to allocate patients to their optimal personalized medicine as compared to "classical" drug testing through phase II/III trials.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Condition  ICMJE Breast Cancer
Intervention  ICMJE
  • Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women)
  • Drug: Neoadjuvant letrozole (postmenopausal women)
  • Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
  • Drug: Neoadjuvant docetaxel + cyclophosphamide
  • Drug: Neoadjuvant docetaxel
  • Drug: Neoadjuvant docetaxel + trastuzumab + pertuzumab
  • Drug: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab
  • Drug: Neoadjuvant olaparib
  • Drug: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
  • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    After response to neoadjuvant treatment
  • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
  • Drug: Adjuvant trastuzumab
  • Drug: Adjuvant letrozole (postmenopausal women)
  • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Drug: Adjuvant palbociclib (if palbociclib given neoadjuvant)
  • Drug: Adjuvant Epirubicin+ Cyclophosphamide
Study Arms  ICMJE
  • Experimental: A
    ER/PGR>50% TP53 wt
    Interventions:
    • Drug: Neoadjuvant tamoxifen + goserelin (premenopausal women)
    • Drug: Neoadjuvant letrozole (postmenopausal women)
    • Drug: Neoadjuvant endocrine therapy + palbociclib (if lack of response to endocrine therapy alone)
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
    • Drug: Adjuvant palbociclib (if palbociclib given neoadjuvant)
    • Drug: Adjuvant Epirubicin+ Cyclophosphamide
  • Experimental: B
    ER/PGR>50% TP53 mutated
    Interventions:
    • Drug: Neoadjuvant docetaxel + cyclophosphamide
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Experimental: C
    ER/PGR<50% TP53 wt
    Interventions:
    • Drug: Neoadjuvant docetaxel
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Experimental: D
    ER/PGR<50% TP53 mutated
    Interventions:
    • Drug: Neoadjuvant docetaxel + cyclophosphamide
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Experimental: E
    HER2+ TP53 wt
    Interventions:
    • Drug: Neoadjuvant docetaxel + trastuzumab + pertuzumab
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant trastuzumab
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Experimental: F
    HER2+ TP53 mutated
    Interventions:
    • Drug: Neoadjuvant docetaxel + cyclophosphamide + trastuzumab + pertuzumab
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
    • Drug: Adjuvant trastuzumab
    • Drug: Adjuvant letrozole (postmenopausal women)
    • Drug: Adjuvant tamoxifen + goserelin (premenopausal women)
  • Experimental: G
    Triple negative breast cancer TP53 wt
    Interventions:
    • Drug: Neoadjuvant olaparib
    • Drug: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
  • Experimental: H
    Triple negative breast cancer TP53 mutated
    Interventions:
    • Drug: Neoadjuvant olaparib
    • Drug: Neoadjuvant cyclophosphamide (after 10 weeks of olaparib alone)
    • Procedure: Breast conserving surgery or mastectomy + SNB/axillary dissection
    • Radiation: Postoperative radiotherapy breast/chest wall + regional lymph nodes
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Active, not recruiting
Actual Enrollment  ICMJE
 (submitted: December 4, 2015)
200
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2030
Actual Primary Completion Date June 1, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Previously untreated, histologically confirmed non-inflammatory breast cancer, >4 cm in diameter and /or metastatic ipsilateral axillary deposits for which the smallest diameter of the largest node >2 cm by CT or ultrasound scan.
  • WHO performance status 0-1
  • Known tumor ER, PGR, HER2 and TP53 status.
  • Known tumor Ki67 percentage (if ER/PGR>50% and TP53 wt status).
  • Distant metastasis not suspected. Patients will undergo radiology exams during screening phase, after signing the informed consent.
  • Age >18 years
  • Patients must have clinically and/or radiographically documented measurable breast cancer according to RECIST.
  • Radiology studies (CT thorax/abdomen and bone scintigraphy/bone scan) must be performed within 28 days prior to registration.
  • Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
  • Before patient registration/randomization, written informed consent must be given according to national and local regulations.
  • For arms B-H:

    • Neutrophils > 1.5 x 109/L
    • Platelets > 100 x 109/L
    • Bilirubin < 2 x upper limit normal (ULN). For patients with Gilbert´s syndrome bilirubin >2 x ULN is accepted if there is no evidence of biliary obstruction.
    • Serum creatinine < 1.5 x ULN
    • ALT and Alk Phos (ALP) <2.5 x ULN
    • INR < 1.5

Exclusion Criteria:

  • Unstable angina pectoris or heart failure
  • Other co-morbidity that, based on the assessment of the treating physician, may preclude the use of chemotherapy at actual doses.
  • Pregnant or lactating patients can not be included.
  • Clinical evidence of serious coagulopathy. Prior arterial/venous thrombosis or embolism does not exclude patients from inclusion, unless patient is considered unfit by study oncologist.
  • Patient not able to give an informed consent or comply with study regulations as deemed by study investigator.
  • Active cystitis (to be treated upfront)
  • Active bacterial infections
  • Urinary obstruction
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Norway
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT02624973
Other Study ID Numbers  ICMJE 2015/8463
Has Data Monitoring Committee Yes
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE
Plan to Share IPD:Yes
Plan Description:Tumor genomic data will be made available after publication.
Responsible Party Haukeland University Hospital
Study Sponsor  ICMJE Haukeland University Hospital
Collaborators  ICMJE
  • Helse Vest
  • Pfizer
  • AstraZeneca
Investigators  ICMJE
Principal Investigator:Hans Petter Eikesdal, MD PhDConsultant oncologist
PRS Account Haukeland University Hospital
Verification Date July 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP